Possible Pharmacological Effect of Quercetin in the Management of Hyperuricemia - Results From Real-life Clinical Studies

NCT06652035 | Completed DMC

• 1 other identifier: 88_18.01.2023_QuercetinFit - A
• Study Type: observational
• Target: 161
• Locations: 1 country
• Sites: 1

Brief Summary

Quercetin, a natural flavonoid found in various fruits and vegetables, has gained attention for its potential role in managing hyperuricemia. Emerging evidence suggests that quercetin may reduce plasma uric acid levels by inhibiting xanthine oxidase, an enzyme responsible for uric acid production. Additionally, its anti-inflammatory and antioxidant properties could help mitigate the oxidative stress and inflammation associated with hyperuricemia. As a result, quercetin supplementation offers a promising avenue for therapeutic intervention in conditions like gout and other uric acid-related disorders.

Conditions

Hyperuricemia

Outcome Measures

Primary Outcomes (1)

• Change in plasma uric acid level

  Supplement effect on plasma uric acid level

  90 days

Secondary Outcomes (11)

• Change in plasma cholesterol level

  90 days

• Change in plasma triglycerides level

  90 days

• Change in plasma glucose level

  90 days

• Change in plasma insulin level

  90 days

• Change in plasma creatine phosphokinase level

  90 days

Study Arms (2)

Supplemental Quercetin group

These participants received oral 500 mg Quevir® (Quercetin Phytosome®) tablet, twice a day for 90 days. Each Quevir® tablet contains 200 mg pure Quercetin.

Dietary Supplement: Quevir® (Quercetin Phytosome®)

Supplemental Probiotic Strptococcus salivarius K12 (ATCC BAA-1024) group

These participants received orally dissolving Bactoblis® tablet, once daily before bedtime for 90 days. Each Bactoblis® tablet contains at least 1x10⁹ CFU of probiotic S. salivarius K12 (ATCC BAA-1024).

Dietary Supplement: Bactoblis®

Interventions

Quevir® (Quercetin Phytosome®) DIETARY_SUPPLEMENT

500 mg Quevir® (Quercetin Phytosome®) tablet

Also known as: Quevir®

Supplemental Quercetin group

Bactoblis® DIETARY_SUPPLEMENT

Probiotic Streptococcus Salivarius K12 (ATCC BAA-1024)

Supplemental Probiotic Strptococcus salivarius K12 (ATCC BAA-1024) group

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

Healthy participants visited the nutritional clinics during the COVID-19 pandemic for general health check up to improve their immunological protection against COVID-19 infection.

You may qualify if:

• Healthy adults
• BMI between 18.5 and 29.9 kg/m²
• Non-smoker
• Consumtion of less than 3 units of alcohol per day

You may not qualify if:

• \- Plasma uric acid concentrations above 7 mg/dL
• Diagnosis of endocrinological, metabolic, oncological, neurological, or bowel inflammatory disease diseases, gout, kidney stones

Sponsors & Collaborators

• Liaquat University of Medical & Health Sciences: lead
• The University of Urbino Carlo Bo, Italy: collaborator

Study Sites (1)

Dr. Buccomino Medical Clinic

Milan, Italy

Location

Related Publications (1)

• Di Pierro F, Rabbani F, Tareen M, Nigar R, Khan A, Zerbinati N, Tanda ML, Cazzaniga M, Bertuccioli A, Falasca P, Damiani G, Villanova N. Potential pharmacological effect of Quercetin Phytosome in the management of hyperuricemia: results from real-life clinical studies. Front Nutr. 2025 Feb 7;12:1519459. doi: 10.3389/fnut.2025.1519459. eCollection 2025.

  PMID: 39990611 DERIVED

MeSH Terms

Conditions

Hyperuricemia

Condition Hierarchy (Ancestors)

Pathologic Processes; Pathological Conditions, Signs and Symptoms

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Professor of Clinical Biochemistry and Experimental Medicine

Study Record Dates

• First Submitted: October 16, 2024
• First Posted: October 22, 2024
• Study Start: September 1, 2021
• Primary Completion: December 31, 2022
• Study Completion: June 15, 2023
• Last Updated: October 29, 2024

Record last verified: 2024-10

Data Sharing

• IPD Sharing: Will not share

Locations

IT (1)